Tumor-associated hepatic microvasculature and surrounding tumor tissue

Tumor-associated hepatic microvasculature and surrounding tumor tissue refers to the complex histological and functional environment where primary or metastatic liver cancers reside. This compartment is distinguished by its unique blood supply; while healthy liver tissue is primarily perfused by the portal vein, malignant liver tumors rely almost exclusively on the hepatic artery for oxygen and nutrients (Mazzaferro et al., 2014, Lancet Oncology). This reliance leads to the development of a dense, disorganized, and highly permeable microvascular network driven by the overproduction of pro-angiogenic factors like Vascular Endothelial Growth Factor (VEGF). The surrounding tumor tissue, or stroma, consists of malignant cells, cancer-associated fibroblasts, and immune cells that interact with these vessels to facilitate tumor progression and evade immune detection (Quail & Joyce, 2013, Nature Medicine). In clinical practice, this entire microenvironment is targeted by systemic multi-kinase inhibitors such as sorafenib and lenvatinib, which disrupt angiogenic signaling, as well as locoregional therapies like transarterial chemoembolization (TACE) and selective internal radiation therapy (SIRT). These treatments exploit the anatomical and physiological abnormalities of the tumor-associated vasculature to deliver targeted damage while minimizing impact on the surrounding healthy liver parenchyma.

Other names

Hepatic tumor microenvironmentTumor-associated liver vasculatureLiver tumor stromaHypervascular liver tumor compartment

Therapeutic intervention involves the inhibition of pro-angiogenic growth factors (e.g., VEGF, PDGF) to normalize or prune tumor vessels, and the use of locoregional techniques to deliver embolic, chemotherapeutic, or radioactive agents directly into the tumor-feeding arterial supply (Llovet et al., 2021, Nature Reviews Disease Primers).